IceCure Medical Ltd (NASDAQ:ICCM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The US$62m market-cap company posted a loss in its most recent financial year of US$15m and a latest trailing-twelve-month loss of US$15m shrinking the gap between loss and breakeven. As path to profitability is the topic on IceCure Medical's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Consensus from 3 of the American Medical Equipment analysts is that IceCure Medical is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$3.9m in 2027. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 60% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving IceCure Medical's growth isn’t the focus of this broad overview, however, keep in mind that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for IceCure Medical

One thing we’d like to point out is that IceCure Medical has no debt on its balance sheet, which is rare for a loss-making growth company, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are too many aspects of IceCure Medical to cover in one brief article, but the key fundamentals for the company can all be found in one place – IceCure Medical's company page on Simply Wall St. We've also put together a list of relevant factors you should further research:

1. Valuation: What is IceCure Medical worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether IceCure Medical is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on IceCure Medical’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.